The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2022 | The prognostic role of t(11;14) in patients with newly diagnosed AL amyloidosis
Despina Fotiou
• 6 Sep 2022
Despina Fotiou, MD, PhD, University of Athens, Athens, Greece, discusses the prognostic impact of t(11;14) in patients with newly diagnosed AL amyloidosis. Dr Fotiou first explains how t(11;14) may decrease patient response to treatment with bortezomib, and then highlights the potential role of BCL2 inhibitors in these patients. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
